Key facts
- This page summarizes Tess Burleson's Form 4 filing for Salarius Pharmaceuticals, Inc. (SLRX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 22 Feb 2024, 16:13.
Tess Burleson - 20 Feb 2024 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)
- Reporting relationship
- Director
- Issuer ticker
- SLRX
- Reported as of
- 20 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Feb 2024, 16:13:07 UTC
- Prior SEC filing
- 05 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/Mark Rosenblum, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Tess Burleson filed Form 4 for Salarius Pharmaceuticals, Inc. (SLRX) on 22 Feb 2024.
Change
- Previous filing in this sequence was filed on 05 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SLRX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +20,500
- Change %
- Price
- $0.000000
- Shares after
- 20,500
- Date
- 20 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,500
- Exercise price
- $0.5711
* marks a reported price that did not pass the local price check.